Blood oxygenation level-dependent activation in basal ganglia nuclei relates to specific symptoms in de novo Parkinson's disease

Movement Disorders

Volumn 25, Issue 13, 2010, Pages 2035-2043

  Prodoehl, Janey ^a   Spraker, Mathew ^b   Corcos, Daniel ^a,b,c   Comella, Cynthia ^c   Vaillancourt, David ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Basal ganglia; BOLD; Disease severity; FMRI; Parkinson's disease

Indexed keywords

ADULT; AGED; ARTICLE; BASAL GANGLION; BLOOD OXYGENATION LEVEL DEPENDENT; BRADYKINESIA; BRAIN NUCLEUS; CAUDATE NUCLEUS; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSIS, MEASUREMENT AND ANALYSIS; DISEASE SEVERITY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLOBUS PALLIDUS; HUMAN; MALE; MOTOR CORTEX; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PRECISION GRIP; PRIORITY JOURNAL; PUTAMEN; RIGIDITY; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYMPTOMATOLOGY; THALAMUS; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGED; BASAL GANGLIA; BRAIN MAPPING; CASE-CONTROL STUDIES; FEMALE; HAND STRENGTH; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OXYGEN; PARKINSON DISEASE; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; THALAMUS;

EID: 78649357984     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23360     Document Type: Article

References (26)

1. Brooks DJ, Frey KA, Marek KL, et al. Assessment of neuro imaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 2003;184(Suppl 1):S68-S79.
2. Lang AE, Mikulis D. A new sensitive imaging biomarker for Parkinson disease? Neurology 2009;72:1374-1375.
3. Vaillancourt DE, Spraker MB, Prodoehl J, et al. High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease. Neurology 2009;72:1378-1384.
4. Wu T, Long X, Zang Y, et al. Regional homogeneity changes in patients with Parkinson's disease. Hum Brain Mapp 2009;30: 1502-1510.
5. Spraker MB, Prodoehl J, Corcos DM, Comella CL, Vaillancourt DE. Basal ganglia hypoactivity during grip force in drug naive Parkinson's disease. Hum Brain Mapp (in press).
6. Stebbins GT, Goetz CG, Lang AE, Cubo E. Factor analysis of the motor section of the unified Parkinson's disease rating scale during the off-state. Mov Disord 1999;14:585-589.
7. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. 19 Neurology 2001;57(Suppl 3): S34-S38.
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
9. Vaillancourt DE, Thulborn KR, Corcos DM. Neural basis for the processes that underlie visually-guided and internally-guided force control in humans. J Neurophysiol 2003;90:3330-3340.
10. Prodoehl J, Yu H, Little DM, Abraham I, Vaillancourt DE. Region of interest template for the human basal ganglia: comparing EPI and standardized space approaches. Neuroimage 2008; 39:956-965.
11. Mayka MA, Corcos DM, Leurgans SE, Vaillancourt DE. Three dimensional locations and boundaries of motor and premotor cortices as defined by functional brain imaging: a meta-analysis. Neuroimage 2006;31:1453-1474.
12. Tabachinick BG, Fidell LS. Using multivariate statistics, Third ed. New York: HarperCollins College Publishers; 1996.
13. 123I-FP-CIT in de novo idiopathic Parkinson's disease patients. Eur J Nucl Med Mol Imaging 2008;35:2220-2226.
14. Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007;130(Part 7):1834-1846.
15. Eshuis SA, Maguire RP, Leenders KL, Jonkman S, Jager PL. Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease. Eur J Nucl Med Mol Imaging 2006;33:200-209.
16. 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-698.
17. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study. Brain 2009;132(Part 11):2970-2979.
18. Djaldetti R, Treves TA, Ziv I, Melamed E, Lampl Y, Lorber-boym M. Use of a single [(123)I]-FP-CIT SPECT to predict the severity of clinical symptoms of Parkinson disease. Neurol Sci (in press).
19. Grafton ST. Contributions of functional imaging to understanding parkinsonian symptoms. Curr Opin Neurobiol 2004;14:715-719.
20. Lozza C, Marie RM, Baron JC. The metabolic substrates of bradykinesia and tremor in uncomplicated Parkinson's disease. Neuroimage 2002;17:688-699.
21. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997;41:58-64.
22. Martinez-Martin P, Gil-Nagel A, Gracia LM, Gomez JB, Martinez-Sarries J, Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure. The Cooperative Multicentric Group. Mov Disord 1994;9:76-83.
23. Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord 1994;9:89-91.
24. Prochazka A, Bennett DJ, Stephens MJ, et al. Measurement of rigidity in Parkinson's disease. Mov Disord 1997;12:24-32.
25. Elble RJ. Origins of tremor. Lancet 2000;355:1113-1114.
26. Rajput AH, Sitte HH, Rajput A, Fenton ME, Pifl C, Hornykiewicz O. Globus pallidus dopamine and Parkinson motor sub types: clinical and brain biochemical correlation. Neurology 2008;70(16 Part 2):1403-1410.